TABLE 3

Various PPIs as inhibitors of diazepam N-demethylation in the presence of human primary hepatocytes coincubated with human serum

PPI (Final Concentration)a% Inhibitionb% Inhibitionin vivo (90% CI)c
Hepatocyte Preparation 1 (n = 1 Organ Donor)Hepatocyte Preparation 2 (Pool of n = 20 Organ Donors)
Omeprazole (2.5 μM)30.2 ± 5.423.2 ± 5.238 (28, 49)d, 46 (28, 61)e
Esomeprazole (18.7 μM)60.1 ± 1.423.6 ± 4.479 (52, 99)
Lansoprazole (2.9 μM)<2<219 (<1, 33)
Dexlansoprazole (2.9 μM)8.0 ± 3.8<210 (2, 19)
Pantoprazole (6.7 μM)<24.9 ± 2.8<1 (<1, 20)
Rabeprazole (1.4 μM)13.5 ± 6.42.8 ± 2.9<1 (<1, 3)
  • a Each PPI was added at a single concentration, based on its estimated Cmax,portal (see Materials and Methods). For dexlansoprazole, it was assumed that its Cmax,portal is identical to that of lansoprazole; assumed an oral dose of 20, 30, 30, 40, and 40 mg for omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole, respectively.

  • b Data are reported as percentage of inhibition, relative to a DMSO alone control, and represent mean ± S.D. of triplicate determinations. In the presence of DMSO alone, the rate of N-desmethyl-diazepam formation was 28 ± 0.4 pmol/min per 106 cells (hepatocyte preparation 1) and 15 ± 0.7 pmol/min per 106 cells (hepatocyte preparation 2). The final diazepam concentration was 1 μM (preparation 1) and 2 μM (preparation 2); close to the estimated Cmax,portal for diazepam (data not shown). Hepatocyte preparation 1 exhibited higher CYP2C19 activity [(S)-mephenytoin 4′-hydroxylase = 95 pmol/min per 106 cells vs. 15 pmol/min per 106 cells].

  • c Percentage of inhibitionin vivo was calculated based on the reported effect of each PPI on the AUC of diazepam (see Materials and Methods, eqs. 17 and 18).

  • d Percentage of inhibitionin vivo was calculated based on the AUCi/AUCc ratio reported by Ishizaki et al. (1995).

  • e Percentage of inhibitionin vivo was calculated based on the AUCi/AUCc ratio reported by Andersson et al. (1990).